These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 19365401)

  • 1. TNF-alpha-308 G/A polymorphism and responsiveness to TNF-alpha blockade therapy in moderate to severe rheumatoid arthritis: a systematic review and meta-analysis.
    O'Rielly DD; Roslin NM; Beyene J; Pope A; Rahman P
    Pharmacogenomics J; 2009 Jun; 9(3):161-7. PubMed ID: 19365401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of TNF-alpha -308 G/A polymorphism with responsiveness to TNF-alpha-blockers in rheumatoid arthritis: a meta-analysis.
    Lee YH; Rho YH; Choi SJ; Ji JD; Song GG
    Rheumatol Int; 2006 Dec; 27(2):157-61. PubMed ID: 16909270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between tumor necrosis factor-α (TNF-α) promoter -308 G/A and response to TNF-α blockers in rheumatoid arthritis: a meta-analysis.
    Zeng Z; Duan Z; Zhang T; Wang S; Li G; Gao J; Ye D; Xu S; Xu J; Zhang L; Pan F
    Mod Rheumatol; 2013 May; 23(3):489-95. PubMed ID: 22760475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations between PTPRC rs10919563 A/G and FCGR2A R131H polymorphisms and responsiveness to TNF blockers in rheumatoid arthritis: a meta-analysis.
    Lee YH; Bae SC
    Rheumatol Int; 2016 Jun; 36(6):837-44. PubMed ID: 27074847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumour necrosis factor alpha -308G->A polymorphism is not associated with response to TNFalpha blockers in Caucasian patients with rheumatoid arthritis: systematic review and meta-analysis.
    Pavy S; Toonen EJ; Miceli-Richard C; Barrera P; van Riel PL; Criswell LA; Mariette X; Coenen MJ
    Ann Rheum Dis; 2010 Jun; 69(6):1022-8. PubMed ID: 19966089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical relevance of switching to a second tumour necrosis factor-alpha inhibitor after discontinuation of a first tumour necrosis factor-alpha inhibitor in rheumatoid arthritis: a systematic literature review and meta-analysis.
    Rémy A; Avouac J; Gossec L; Combe B
    Clin Exp Rheumatol; 2011; 29(1):96-103. PubMed ID: 21269578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients.
    Seitz M; Wirthmüller U; Möller B; Villiger PM
    Rheumatology (Oxford); 2007 Jan; 46(1):93-6. PubMed ID: 16720636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associations between tumor necrosis factor-alpha (TNF-alpha) -308 and -238 G/A polymorphisms and shared epitope status and responsiveness to TNF-alpha blockers in rheumatoid arthritis: a metaanalysis update.
    Lee YH; Ji JD; Bae SC; Song GG
    J Rheumatol; 2010 Apr; 37(4):740-6. PubMed ID: 20194454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.
    Cañete JD; Suárez B; Hernández MV; Sanmartí R; Rego I; Celis R; Moll C; Pinto JA; Blanco FJ; Lozano F
    Ann Rheum Dis; 2009 Oct; 68(10):1547-52. PubMed ID: 18930989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic review and meta-analysis: pharmacogenetics of anti-TNF treatment response in rheumatoid arthritis.
    Bek S; Bojesen AB; Nielsen JV; Sode J; Bank S; Vogel U; Andersen V
    Pharmacogenomics J; 2017 Oct; 17(5):403-411. PubMed ID: 28607508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of anti-CCP positivity and carriage of TNFRII susceptibility variant with anti-TNF-α response in rheumatoid arthritis.
    Vasilopoulos Y; Bagiatis V; Stamatopoulou D; Zisopoulos D; Alexiou I; Sarafidou T; Settas L; Sakkas L; Mamouris Z
    Clin Exp Rheumatol; 2011; 29(4):701-4. PubMed ID: 21813066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Confirmation of -174G/C interleukin-6 gene promoter polymorphism as a genetic marker predicting antitumor necrosis factor treatment outcome.
    Dávila-Fajardo CL; Márquez A; Pascual-Salcedo D; Moreno Ramos MJ; García-Portales R; Magro C; Alegre-Sancho JJ; Balsa A; Cabeza-Barrera J; Raya E; Martín J
    Pharmacogenet Genomics; 2014 Jan; 24(1):1-5. PubMed ID: 24253594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of the FcGRIIIa polymorphism in modifying the association between treatment and outcome in patients with rheumatoid arthritis treated with rituximab versus TNF-α antagonist therapies.
    Sarsour K; Greenberg J; Johnston JA; Nelson DR; O'Brien LA; Oddoux C; Ostrer H; Pearlman A; Reed G
    Clin Exp Rheumatol; 2013; 31(2):189-94. PubMed ID: 23294992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of associations between polymorphisms within genes coding for tumour necrosis factor (TNF)-alpha and TNF receptors and responsiveness to TNF-alpha blockers in patients with rheumatoid arthritis.
    Swierkot J; Bogunia-Kubik K; Nowak B; Bialowas K; Korman L; Gebura K; Kolossa K; Jeka S; Wiland P
    Joint Bone Spine; 2015 Mar; 82(2):94-9. PubMed ID: 25311255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The presence of anti-citrullinated protein antibodies (ACPA) does not affect the clinical response to adalimumab in a group of RA patients with the tumor necrosis factor (TNF) α-308 G/G promoter polymorphism.
    Soto L; Sabugo F; Catalan D; Wurmann P; Cermenatti T; Gatica H; Aravena O; Salazar L; Aguillón JC; Cuchacovich M
    Clin Rheumatol; 2011 Mar; 30(3):391-5. PubMed ID: 21234628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor necrosis factor-alpha receptor II polymorphism in patients from southern Europe with mild-moderate and severe rheumatoid arthritis.
    Fabris M; Tolusso B; Di Poi E; Assaloni R; Sinigaglia L; Ferraccioli G
    J Rheumatol; 2002 Sep; 29(9):1847-50. PubMed ID: 12233877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.
    Finckh A; Ciurea A; Brulhart L; Kyburz D; Möller B; Dehler S; Revaz S; Dudler J; Gabay C;
    Arthritis Rheum; 2007 May; 56(5):1417-23. PubMed ID: 17469098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Replication of association of the PTPRC gene with response to anti-tumor necrosis factor therapy in a large UK cohort.
    Plant D; Prajapati R; Hyrich KL; Morgan AW; Wilson AG; Isaacs JD; ; Barton A
    Arthritis Rheum; 2012 Mar; 64(3):665-70. PubMed ID: 21952740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumour necrosis factor-alpha (TNF-alpha) levels and influence of -308 TNF-alpha promoter polymorphism on the responsiveness to infliximab in patients with rheumatoid arthritis.
    Cuchacovich M; Ferreira L; Aliste M; Soto L; Cuenca J; Cruzat A; Gatica H; Schiattino I; Pérez C; Aguirre A; Salazar-Onfray F; Aguillón JC
    Scand J Rheumatol; 2004; 33(4):228-32. PubMed ID: 15370717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.